Modality
Nanobody
MOA
BCMA ADC
Target
AHR
Pathway
mTOR
MSHemophilia A
Development Pipeline
Preclinical
~Aug 2015
→ ~Nov 2016
Phase 1
~Feb 2017
→ ~May 2018
Phase 2
~Aug 2018
→ ~Nov 2019
Phase 3
Feb 2020
→ Jul 2028
Phase 3Current
NCT04104768
145 pts·Hemophilia A
2020-02→2028-03·Not yet recruiting
NCT04537324
1,077 pts·MS
2024-05→2028-07·Active
1,222 total pts2 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2028-03-142.0y awayPh3 Readout· Hemophilia A
2028-07-162.3y awayPh3 Readout· MS
Trial Timeline
2020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3
P3
Not yet…
P3
Active
Catalysts
Ph3 Readout
2028-03-14 · 2.0y away
Hemophilia A
Ph3 Readout
2028-07-16 · 2.3y away
MS
ActiveNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04104768 | Phase 3 | Hemophilia A | Not yet recr... | 145 | Safety |
| NCT04537324 | Phase 3 | MS | Active | 1077 | HbA1c |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2901 | Pfizer | Phase 2 | AHR | |
| AZN-1715 | AstraZeneca | Phase 3 | AHR | |
| AZN-3724 | AstraZeneca | Preclinical | PSMA | |
| Olpatinib | GSK | Preclinical | PD-L1 | |
| BAY-6520 | Bayer | Phase 2 | AHR | |
| GIL-9779 | Gilead Sciences | Phase 1 | IL-17A | |
| Semasacituzumab | Jazz Pharma | Phase 2 | AHR | |
| Sematenlimab | Samsung Biologics | Phase 3 | PI3Kα | |
| Doxalemzoparlimab | Nuvalent | Approved | AHR | |
| CRS-184 | CRISPR Therapeutics | Phase 1/2 | AHR |